PURPOSE: The mode of action of targeted cancer agents (TCAs) differs from classic chemotherapy, which leads to concerns about the role of RECIST in evaluating tumor response in trials with TCAs. We investigated the performance of RECIST using a pooled database from 50 clinical trials with at least one TCA. METHODS: We examined the impact of the number of target lesions (TLs) on within-patient variability of tumor response. The prognostic effect of TL response (at 12 weeks or on study on the basis of a maximum five TLs) on survival was studied through landmark and time-dependent Cox models adjusted for baseline tumor load, occurrence of new lesions, or unequivocal progression of nontarget disease. RESULTS: Data were obtained from 23,259 pati...
OBJECTIVE: Our retrospective study compared Response Evaluation Criteria in Solid Tumors (RECIST) ve...
Response Evaluation Criteria In Solid Tumours (RECIST) remain an integral part of the assessment of ...
Objective criteria for measuring response to cancer treatment are critical to clinical research and ...
PURPOSE The mode of action of targeted cancer agents (TCAs) differs from classic chemotherapy, which...
PURPOSE The mode of action of targeted cancer agents (TCAs) differs from classic chemotherapy, which...
International audienceBackground Response Evaluation Criteria in Solid Tumors (RECIST) are widely us...
Background: After the initial RECIST 1.0 were published in 2000, the criteria were widely implemente...
Background: To accelerate drug approvals while maintaining scientific rigor in the evaluation of a ...
Purpose: With the increasing use of novel targeted agents and the development of high imaging techni...
(RECIST 1.1) guideline states that the two largest lesions per organ should be measured as target le...
Purpose: With the increasing use of novel targeted agents and the development of high imaging techni...
Response evaluation criteria in solid tumours (RECIST) v1.1 are currently the reference standard for...
Response evaluation criteria in solid tumours (RECIST) v1.1 are currently the reference standard fo...
Response evaluation criteria in solid tumours (RECIST) v1.1 are currently the reference standard for...
Response evaluation criteria in solid tumours (RECIST) v1.1 are currently the reference standard for...
OBJECTIVE: Our retrospective study compared Response Evaluation Criteria in Solid Tumors (RECIST) ve...
Response Evaluation Criteria In Solid Tumours (RECIST) remain an integral part of the assessment of ...
Objective criteria for measuring response to cancer treatment are critical to clinical research and ...
PURPOSE The mode of action of targeted cancer agents (TCAs) differs from classic chemotherapy, which...
PURPOSE The mode of action of targeted cancer agents (TCAs) differs from classic chemotherapy, which...
International audienceBackground Response Evaluation Criteria in Solid Tumors (RECIST) are widely us...
Background: After the initial RECIST 1.0 were published in 2000, the criteria were widely implemente...
Background: To accelerate drug approvals while maintaining scientific rigor in the evaluation of a ...
Purpose: With the increasing use of novel targeted agents and the development of high imaging techni...
(RECIST 1.1) guideline states that the two largest lesions per organ should be measured as target le...
Purpose: With the increasing use of novel targeted agents and the development of high imaging techni...
Response evaluation criteria in solid tumours (RECIST) v1.1 are currently the reference standard for...
Response evaluation criteria in solid tumours (RECIST) v1.1 are currently the reference standard fo...
Response evaluation criteria in solid tumours (RECIST) v1.1 are currently the reference standard for...
Response evaluation criteria in solid tumours (RECIST) v1.1 are currently the reference standard for...
OBJECTIVE: Our retrospective study compared Response Evaluation Criteria in Solid Tumors (RECIST) ve...
Response Evaluation Criteria In Solid Tumours (RECIST) remain an integral part of the assessment of ...
Objective criteria for measuring response to cancer treatment are critical to clinical research and ...